Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. has extended its strategic financing agreement with Streeterville Capital, LLC, pushing the deadline for completing a qualifying financing of at least $2.6 million from June 15, 2026, to August 31, 2026. This extension provides Vivos with additional time to raise equity and commence a planned rights offering. Streeterville Capital has reaffirmed its commitment to convert up to $4.5 million of its outstanding debt into a combination of preferred and common stock, contingent on Vivos raising the $2.6 million. The move is intended to strengthen Vivos' stockholders' equity and help maintain its Nasdaq listing compliance.

Vivos Therapeutics, Inc. announced its intention to file a registration statement for a proposed rights offering. The offering would distribute transferable subscription rights to shareholders as a dividend. Each right is expected to allow the holder to purchase one share of common stock at an exercise price based on a floor of $1.25 or a premium to the market price. The rights are intended to be listed for trading and exercisable for nine months, with a potential subsequent right upon exercise. The offering is subject to SEC effectiveness, shareholder approval, and other conditions.

Vivos Therapeutics, Inc. has entered into a Collaboration Agreement with South Palm Cardiovascular Associates, LLC (SPCVA) to form AIM Florida, LLC. This new entity will function as a management services organization providing administrative and non-clinical support to clinical entities focused on sleep apnea diagnosis and treatment. Vivos expects to hold at least 80% of AIM Florida's membership interests, with SPCVA holding up to 20%. The collaboration initially targets the Palm Beach County, Florida market and is seen as a scalable model for future expansion nationwide.

Vivos Therapeutics, Inc. announced its intention to file a registration statement with the SEC for a proposed rights offering. This offering aims to distribute transferable subscription rights to shareholders as a dividend, providing the company with additional capital for operations and general corporate purposes. Preliminary terms include an exercise price of the greater of $1.25 per share or 20% above market, a 9-month exercise period, and a subsequent 'exploding' right. The offering is subject to SEC effectiveness, shareholder approval, and other conditions, with no assurance of completion.

Vivos Therapeutics, Inc. announced a collaboration agreement with South Palm Cardiovascular Associates (SPCVA) to establish AIM Florida, LLC. This new management services organization aims to expand access to integrated diagnostic and therapeutic clinical treatment services for cardiovascular disease patients in Florida who also suffer from obstructive sleep apnea (OSA) and insomnia. Vivos expects to hold at least 80% of AIM Florida, with SPCVA holding up to 20%. The company projects the model to contribute to cash flow and profitability, with an initial Sleep Optimization Team generating over $6 million annually with contribution margins approaching 50%.

Vivos Therapeutics, Inc. announced that its CEO, Kirk Hunstman, will participate in The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City. Mr. Hunstman is scheduled to deliver a corporate presentation at 11:30 am ET and will also engage in one-on-one meetings with pre-qualified investors throughout the day. A live webcast and replay of the presentation will be accessible via the company's investor relations website.

Vivos Therapeutics, Inc. has entered into a binding Exchange Agreement with its senior secured lender, Streeterville Capital, LLC, to exchange up to $4.5 million of outstanding debt into a combination of preferred and common stock. This transaction is contingent upon Vivos successfully raising at least $2.6 million in a First Tranche Financing and an additional $1.9 million in a Second Tranche Financing by June 15, 2026. The exchange is intended to bolster Vivos' stockholders' equity to meet Nasdaq listing requirements and will also involve a suspension of debt repayments and a reduction in monthly redemption amounts for Streeterville. The maturity date of the original loan will be extended by six months.

Vivos Therapeutics, Inc. announced a binding agreement with its senior lender, Streeterville Capital, LLC, to exchange up to $4.5 million of outstanding debt into a combination of perpetual preferred stock and common stock. This agreement also includes a 90-day suspension of debt repayment calls and a 60-day suspension of Streeterville's sales of Company securities. The debt-to-equity exchange is contingent on the completion of new equity financings and aims to improve the Company's stockholders' equity, comply with Nasdaq listing standards, and enhance cash flow and liquidity by reducing debt service obligations.

Vivos Therapeutics reported a significant increase in net loss to $(7.75) million for Q1 2026, up from $(3.86) million in Q1 2025. Despite the widened loss, total revenue surged by 70.4% to $5.14 million, primarily driven by a 207.6% increase in service revenue, reflecting the company's strategic pivot to a medical-provider focused sales model. This new strategy includes the June 2025 acquisition of The Sleep Center of Nevada and the formation of AIM Detroit LLC in July 2025.

Vivos Therapeutics reported a 70% year-over-year revenue increase to $5.1 million for the first quarter ended March 31, 2026, largely driven by the acquisition of The Sleep Center of Nevada Management (SCN) and its business model pivot. Gross profit more than doubled to $3.1 million, with gross margin improving to 60%. However, the company's net loss also doubled to $7.8 million, primarily due to increased operating expenses related to business expansion and one-time costs. Vivos is actively working on integrating SCN, increasing productivity, securing new funding, and restructuring debt to improve stockholders' equity and reduce cash burn.